LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on ...

In addition to the proxy statement, STAAR has reached out to all stockholders to ask for their vote to adopt the merger ...

The studies compared the Unity Vitreoretinal Cataract System (VCS) to the Constellation Vision System and the ...

Alcon (NYSE: ALC) shares registered just barely in the plus column Tuesday. The company, purporting to be the global leader in eye care dedicated to helping people see brilliantly, announced results ...

In conjunction with the definitive proxy filing, Staar (STAA) is mailing the following letter to Staar stockholders: “On August 5, 2025, we ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it has filed its ...

Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with ...

Alcon (ALC) announced results from time and motion studies demonstrating efficiency with Unity Vitreoretinal Cataract System for vitreoretinal and ...

Part of Alcon's motivations for continuing to pursue the lawsuit relates to an upcoming TV series based on the movie. The company expressed that it wants to distance itself from Tesla and Elon Musk.

Some claims have been dismissed in the suit, which also involves Warner Bros., about imagery used at a 2024 Tesla event—but ...

Broadwood的申请标志着首个针对Alcon交易的有组织抵制活动。在其声明中，Broadwood指控STAAR董事会与Alcon进行了"实质上排他性"的谈判，几乎没有给其他感兴趣的各方机会提出竞争性报价。

Investing.com - STAAR Surgical Company (NASDAQ:STAA)向Alcon AG (NYSE:ALC)的有争议的出售案在其最大股东采取正式步骤发起代理权争夺以阻止每股28美元的合并后进一步升级。